Kineta KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
About The Event
Join us for a virtual KOL event with Kineta, featuring immunology expert Michael A. Curran, PhD (MD Anderson Cancer Center Department of Immunology) who will discuss key challenges with current cancer therapies and the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment (TME) and drive anti-tumor activity.
Evan Y. Yu, MD (Fred Hutch Cancer Center) will join Kineta leadership to discuss immuno-oncology clinical trials and review the new positive monotherapy data from the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors.
A live question and answer session will follow the formal presentations.